Efficacy of initial combination therapy with anti-SARS-CoV-2 antivirals targeting viral clearance in COVID-19 patients with B-cell lymphoma treated with anti-CD20 antibodies: A retrospective single-centre study in Japan

IF 1.9 4区医学 Q3 INFECTIOUS DISEASES

Journal of Infection and Chemotherapy Pub Date : 2025-05-07 DOI:10.1016/j.jiac.2025.102726

Shuhei Maruyama , Daiki Wada , Akira Inoue , Masami Kashihara , Junya Shimazaki , Fukuki Saito , Kazuyoshi Ishii , Yasushi Nakamori , Yasuyuki Kuwagata

{"title":"Efficacy of initial combination therapy with anti-SARS-CoV-2 antivirals targeting viral clearance in COVID-19 patients with B-cell lymphoma treated with anti-CD20 antibodies: A retrospective single-centre study in Japan","authors":"Shuhei Maruyama , Daiki Wada , Akira Inoue , Masami Kashihara , Junya Shimazaki , Fukuki Saito , Kazuyoshi Ishii , Yasushi Nakamori , Yasuyuki Kuwagata","doi":"10.1016/j.jiac.2025.102726","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>There is no clear treatment strategy for persistent COVID-19 infection that enables clinicians to effectively achieve viral clearance, determine the optimal time to discontinue treatment, and prevent virus reactivation. This retrospective, single-centre study aimed to analyse the effectiveness of antiviral therapies in COVID-19 patients with B-cell lymphoma receiving anti-CD20 therapy.</div></div><div><h3>Methods</h3><div>Conducted at Kansai Medical University Medical Center between January 2022 and October 2024, the study examined the impact of various antiviral regimens and factors on time to viral clearance, defined as SARS-CoV-2 viral load <1 copy/μL by nasopharyngeal swab.</div></div><div><h3>Results</h3><div>Sixty-seven cases met the inclusion criteria, with 40 having a history of bendamustine use, and 33 with combination antiviral therapy as the initial treatment. A multivariable Cox proportional hazards model revealed combination antiviral therapy as the initial regimen (HR 0.36, 95 % CI 0.20–0.65, p < 0.001) significantly shortened time to viral clearance, while bendamustine use (HR 2.74, 95 % CI 1.53–4.89, p < 0.001) significantly prolonged time to viral clearance.</div></div><div><h3>Conclusion</h3><div>This study showed the potential of early combination antiviral therapy to shorten the time to viral clearance in this high-risk patient population.</div></div>","PeriodicalId":16103,"journal":{"name":"Journal of Infection and Chemotherapy","volume":"31 7","pages":"Article 102726"},"PeriodicalIF":1.9000,"publicationDate":"2025-05-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Infection and Chemotherapy","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1341321X25001230","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

There is no clear treatment strategy for persistent COVID-19 infection that enables clinicians to effectively achieve viral clearance, determine the optimal time to discontinue treatment, and prevent virus reactivation. This retrospective, single-centre study aimed to analyse the effectiveness of antiviral therapies in COVID-19 patients with B-cell lymphoma receiving anti-CD20 therapy.

Methods

Conducted at Kansai Medical University Medical Center between January 2022 and October 2024, the study examined the impact of various antiviral regimens and factors on time to viral clearance, defined as SARS-CoV-2 viral load <1 copy/μL by nasopharyngeal swab.

Results

Sixty-seven cases met the inclusion criteria, with 40 having a history of bendamustine use, and 33 with combination antiviral therapy as the initial treatment. A multivariable Cox proportional hazards model revealed combination antiviral therapy as the initial regimen (HR 0.36, 95 % CI 0.20–0.65, p < 0.001) significantly shortened time to viral clearance, while bendamustine use (HR 2.74, 95 % CI 1.53–4.89, p < 0.001) significantly prolonged time to viral clearance.

Conclusion

This study showed the potential of early combination antiviral therapy to shorten the time to viral clearance in this high-risk patient population.

查看原文本刊更多论文

抗cd20抗体治疗的COVID-19 b细胞淋巴瘤患者初始联合抗sars - cov -2抗病毒药物清除病毒的疗效：日本的一项回顾性单中心研究

目的针对持续性COVID-19感染，尚无明确的治疗策略，使临床医生能够有效地实现病毒清除，确定最佳停药时间，并防止病毒再激活。这项回顾性、单中心研究旨在分析接受抗cd20治疗的COVID-19 b细胞淋巴瘤患者抗病毒治疗的有效性。方法该研究于2022年1月至2024年10月在关西医科大学医学中心进行，研究了各种抗病毒方案和因素对病毒清除时间的影响，定义为SARS-CoV-2病毒载量为1拷贝/μL。结果67例符合纳入标准，其中40例有苯达莫司汀使用史，33例为初始联合抗病毒治疗。多变量Cox比例风险模型显示联合抗病毒治疗为初始方案(HR 0.36, 95% CI 0.20-0.65, p <；0.001)显著缩短了病毒清除时间，而苯达莫司汀的使用(HR 2.74, 95% CI 1.53-4.89, p <；0.001)显著延长了清除病毒的时间。结论早期联合抗病毒治疗可缩短高危人群的病毒清除时间。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Infection and Chemotherapy INFECTIOUS DISEASES-PHARMACOLOGY & PHARMACY

CiteScore

4.10

自引率

4.50%

发文量

303

审稿时长

47 days

期刊介绍： The Journal of Infection and Chemotherapy (JIC) — official journal of the Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases — welcomes original papers, laboratory or clinical, as well as case reports, notes, committee reports, surveillance and guidelines from all parts of the world on all aspects of chemotherapy, covering the pathogenesis, diagnosis, treatment, and control of infection, including treatment with anticancer drugs. Experimental studies on animal models and pharmacokinetics, and reports on epidemiology and clinical trials are particularly welcome.